Ra Pharma Announces Pricing Of Initial Public Offering
Published: Oct 26, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (“Ra Pharmaceuticals” or “Ra”), a clinical stage biopharmaceutical company focusing on using its proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system, a critical component of the immune system, today announced the pricing of its initial public offering of 7,049,230 shares of common stock at a public offering price of $13.00 per share. In addition, Ra has granted the underwriters a 30-day option to purchase up to 1,057,385 additional shares of common stock at the initial public offering price, less the underwriting discount. Ra’s common stock is expected to begin trading on the NASDAQ Global Market under the ticker symbol "RARX" on October 26, 2016.
Credit Suisse Securities (USA) LLC, Jefferies LLC, and BMO Capital Markets Corp. are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey is acting as lead manager.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 25, 2016. The offering will be made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained, when available, from: Credit Suisse Securities (USA) LLC, Attn: Prospectus Dept., One Madison Avenue, New York, NY 10010, by telephone at 800- 221-1037 or by email at email@example.com; Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-547-6340 or by email at Prospectus_Department@Jefferies.com; or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, telephone: (800) 414-3627, email: firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.